Expansion Opportunity Olema Oncology is expanding its presence with a new headquarters in South San Francisco and a 38,000 square-foot office lease, signaling capacity to accelerate clinical development collaborations and regional access for partners and customers.

Strategic Partnerships Active collaboration with Bayer and ongoing Phase 1/Phase 3 programs in palazestrant (OP-1250) plus a KAT6 inhibitor OP-3136 create avenues for co-development, licensing, and joint clinical trials with larger biotech and pharma players seeking breast cancer targeted therapies.

Late-Stage Focus Lead program palazestrant is progressing into multiple Phase 3 trials, indicating near-term potential for commercialization readiness and attractive timelines for payor conversations, market access planning, and strategic partnerships around registrational studies.

Diversified Pipeline A complementary portfolio including OP-3136, a KAT6 inhibitor in Phase 1, plus PROTAC-enabled modalities, provides cross-promotional opportunities across oncology indications and potential for multi-asset licensing deals with broader oncology franchises.

Access and Awareness Public engagement through major oncology events like ASCO and ongoing clinical data presentations enhance brand visibility and create speaking, sponsorship, and alliance opportunities with hospitals, research institutions, and patient advocacy groups.